(Q35068031)

6 August 2017

1 reference

title

Current management of primary biliary cirrhosis and primary sclerosing cholangitis (English)

1 reference

primary sclerosing cholangitis

6 August 2017

main subject

ascending cholangitis

0 references

1 reference

primary biliary cholangitis

inferred from title

0 references

author name string

Cynthia Levy

series ordinal

1

1 reference

6 August 2017

Keith D Lindor

series ordinal

2

1 reference

6 August 2017

publication date

1 January 2003

1 reference

6 August 2017

published in

Journal of Hepatology

1 reference

6 August 2017

volume

38 Suppl 1

1 reference

6 August 2017

page(s)

S24-37

1 reference

Low prevalence of primary biliary cirrhosis in Victoria, Australia. Melbourne Liver Group

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Risk factors for primary biliary cirrhosis in a cohort of patients from the united states

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Fatigue in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

The prognostic importance of clinical and histologic features in asymptomatic and symptomatic primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Randomized trial of chlorambucil for primary biliary cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Cyclosporin A treatment in primary biliary cirrhosis: results of a long-term placebo controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

A controlled trial of prednisolone treatment in primary biliary cirrhosis. Three-year results

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

A controlled trial of cyclosporine in the treatment of primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

A prospective trial of colchicine for primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

A controlled trial of colchicine in primary biliary cirrhosis. Trial design and preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Evaluation of colchicine therapy in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Long-term follow-up of patients with primary biliary cirrhosis on colchicine therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

A placebo-controlled trial of primary biliary cirrhosis treatment with colchicine and ursodeoxycholic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Effect of ursodeoxycholic acid on the kinetics of the major hydrophobic bile acids in health and in chronic cholestatic liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Tauroursodeoxycholic acid stimulates hepatocellular exocytosis and mobilizes extracellular Ca++ mechanisms defective in cholestasis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Tauroursodeoxycholic acid activates protein kinase C in isolated rat hepatocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Tauroursodeoxycholic acid inserts the apical conjugate export pump, Mrp2, into canalicular membranes and stimulates organic anion secretion by protein kinase C-dependent mechanisms in cholestatic rat liver

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Ursodeoxycholic acid for primary biliary cirrhosis: lessons from the past--issues for the future

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Ursodeoxycholic acid for primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Ursodeoxycholic acid in the treatment of primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Ursodeoxycholic acid treatment in patients with primary biliary cirrhosis. A Swedish multicentre, double-blind, randomized controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Characterisation of patients with primary biliary cirrhosis responding to long term ursodeoxycholic acid treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Effect of pretransplantation ursodeoxycholic acid therapy on the outcome of liver transplantation in patients with primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Effect of ursodeoxycholic acid on serum lipids of patients with primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Autoimmune conditions associated with primary biliary cirrhosis: response to ursodeoxycholic acid therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

A randomized trial in primary biliary cirrhosis comparing ursodeoxycholic acid in daily doses of either 10 mg/kg or 20 mg/kg. Dutch Multicentre PBC Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Optimum dose of ursodeoxycholic acid in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Characterisation of patients with a complete biochemical response to ursodeoxycholic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Incomplete response to ursodeoxycholic acid in primary biliary cirrhosis: is a double dosage worthwhile?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Positive responses to methotrexate and ursodeoxycholic acid in patients with primary biliary cirrhosis responding insufficiently to ursodeoxycholic acid alone

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

The combination of ursodeoxycholic acid and methotrexate for primary biliary cirrhosis is not better than ursodeoxycholic acid alone

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Ursodeoxycholic acid and prednisolone versus ursodeoxycholic acid and placebo in the treatment of early stages of primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Triple therapy with ursodeoxycholic acid, prednisone and azathioprine in primary biliary cirrhosis: a 1-year randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

A randomized trial comparing colchicine and ursodeoxycholic acid combination to ursodeoxycholic acid in primary biliary cirrhosis. UDCA-PBC Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Effects of additional administration of colchicine in ursodeoxycholic acid-treated patients with primary biliary cirrhosis: a prospective randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Combination therapy of bezafibrate and ursodeoxycholic acid in primary biliary cirrhosis: a preliminary study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Effect of bezafibrate in primary biliary cirrhosis: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Is bezafibrate histologically effective for primary biliary cirrhosis?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Bezafibrate in the treatment of primary biliary cirrhosis: comparison with ursodeoxycholic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Investigation into the efficacy of bezafibrate against primary biliary cirrhosis, with histological references from cases receiving long term monotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Efficacy of liver transplantation in patients with primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Transplantation for primary biliary cirrhosis: retrospective analysis of 400 patients in a single center

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Optimal timing of liver transplantation for primary biliary cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Confirmation of the role of the Mayo Risk Score as a predictor of resource utilization after orthotopic liver transplantation for primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Etiology and natural history of primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Hepatic and extrahepatic malignancies in primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

A double-blind controlled trial of oral-pulse methotrexate therapy in the treatment of primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Oral budesonide in the treatment of primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Colchicine treatment of primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Pirfenidone in the treatment of primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Oral nicotine in treatment of primary sclerosing cholangitis: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

No beneficial effects of transdermal nicotine in patients with primary sclerosing cholangitis: results of a randomized double-blind placebo-controlled cross-over study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

A pilot study of pentoxifylline for the treatment of primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

An open-label pilot trial of cladibrine (2-cholordeoxyadenosine) in patients with primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Ursodeoxycholic acid therapy for primary sclerosing cholangitis: results of a 2-year randomized controlled trial to evaluate single versus multiple daily doses

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Combined Therapy with Azathioprine, Prednisolone, and Ursodiol in Patients with Primary Sclerosing Cholangitis: A Case Series

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Beneficial effect of bezafibrate on primary sclerosing cholangitis (three case reports).

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Biliary lavage with corticosteroids in primary sclerosing cholangitis. A clinical, cholangiographic and bacteriological study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Endoscopic stent therapy for dominant extrahepatic bile duct strictures in primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Impact of endoscopic therapy on the survival of patients with primary sclerosing cholangitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Efficacy of ursodeoxycholic acid treatment and endoscopic dilation of major duct stenoses in primary sclerosing cholangitis. An 8-year prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Surgical treatment for primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Liver transplantation for primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Biliary malignancies in primary sclerosing cholangitis: timing for liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Liver transplantation for cholangiocarcinoma: results in 207 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Primary sclerosing cholangitis: liver transplantation or biliary surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Recurrence of primary sclerosing cholangitis following liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Effects of naloxone infusions in patients with the pruritus of cholestasis. A double-blind, randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

A controlled trial of naloxone infusions for the pruritus of chronic cholestasis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Oral naltrexone treatment for cholestatic pruritus: A double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Open-label trial of oral nalmefene therapy for the pruritus of cholestasis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Relief of cholestatic pruritus by a novel class of drugs: 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists: effectiveness of ondansetron

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Role of hyperbilirubinemia in the impairment of osteoblast proliferation associated with cholestatic jaundice

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Rates of cancellous bone remodeling and turnover in osteopenia associated with primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Vitamin K and metabolic bone disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Bone disease in primary biliary cirrhosis: independent indicators and rate of progression.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Osteoporosis in primary biliary cirrhosis revisited

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Bone disease in patients with primary sclerosing cholangitis: prevalence, severity and prediction of progression.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II).

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Etidronate for osteoporosis in primary biliary cirrhosis: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Etidronate versus fluoride for treatment of osteopenia in primary biliary cirrhosis: preliminary results after 2 years

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

A 3-year pilot study with 1,25-dihydroxyvitamin D, calcium, and calcitonin for severe osteodystrophy in primary biliary cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Vitamin K2 (menatetrenone) effectively prevents fractures and sustains lumbar bone mineral density in osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Fat-soluble vitamin levels in patients with primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Serum lipid and fat-soluble vitamin levels in primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Multicentre randomized placebo-controlled trial of ursodeoxycholic acid with or without colchicine in symptomatic primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Ten-year combination treatment with colchicine and ursodeoxycholic acid for primary biliary cirrhosis: a double-blind, placebo-controlled trial on symptomatic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

Epidemiology and natural history of primary biliary cirrhosis in a US community

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900006-0

7 January 2021

10.1016/S0168-8278(03)00006-0

Identifiers

DOI

1 reference

6 August 2017

1 reference